Scarica l'app Stockscreener
0.00
100.00%
-0.735
Dopo l'orario di chiusura:
.29
0.29
+
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ATXI Giù?
Forum
Previsione
Frazionamento azionario
Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - The Manila Times
Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - msn.com
Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com
Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView
Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan
Turn Therapeutics secures $25M loan facility from Avenue Capital - investing.com
Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering - Sahm
Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - marketscreener.com
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering - Sahm
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
Neurology stocks rebound in 2025 after midyear slump - BioWorld MedTech
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
Tangible book value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Net current asset value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Viridian Therapeutics (NASDAQ:VRDN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights
Halozyme Therapeutics, Inc. $HALO Shares Sold by Cary Street Partners Financial LLC - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
ATXI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Avenue Therapeutics to develop add-on Pompe disease treatment - Pompe Disease News
Avenue Therapeutics Licenses ATX-04 for Pompe Disease - The Globe and Mail
Avenue Therapeutics licenses ATX-04 for Pompe disease treatment By Investing.com - Investing.com Australia
Avenue Therapeutics (OTC: ATXI) licenses ATX-04 Pompe therapy from Duke - Stock Titan
Avenue Therapeutics licenses ATX-04 for Pompe disease treatment - Investing.com
After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan
Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire
Rare muscle disease drug deal: Avenue backs ATX-04 for Pompe - Stock Titan
Lion Street Advisors LLC Buys 5,619 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Candel Therapeutics Announces Pricing of Public Offering - The Manila Times
Ikarian Capital discloses 4.1% Avenue Therapeutics (ATXI) stake in 13G/A - Stock Titan
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen - MarketBeat
Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat
Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded by Wall Street Zen to Sell - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street - The Joplin Globe
Axsome Therapeutics says AXS-12 NDA submission on track for January - MSN
Century Therapeutics (NASDAQ:IPSC) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Raised to "Buy" at Wall Street Zen - MarketBeat
TMC the metals (NASDAQ:TMC) vs. Canadian Zeolite (OTCMKTS:IZCFF) Critical Review - Defense World
Analyzing Turn Therapeutics (TTRX) & The Competition - Defense World
HCA Healthcare (NYSE:HCA) Shares Gap Up After Earnings Beat - Defense World
Boku (LON:BOKU) Insider Jonathan Peter Prideaux Sells 325,000 Shares of Stock - Defense World
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - Morningstar
Stoke Therapeutics Expands with New Long-Term Waltham Headquarters - TipRanks
Century Therapeutics (NASDAQ:IPSC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Wall Street Zen Upgrades Edgewise Therapeutics (NASDAQ:EWTX) to "Hold" - MarketBeat
Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Cut to "Sell" at Wall Street Zen - MarketBeat
More cash flows into biotechs during conference week: Finance Report - biocentury.com
Aptevo Therapeutics (NASDAQ: APVO) seeks OK for $60M SEPA share sales - Stock Titan
Market Recap: Can Ernexa Therapeutics Inc continue delivering strong returnsJuly 2025 PostEarnings & Low Risk High Reward Ideas - baoquankhu1.vn
Avenue Therapeutics shareholders elect directors, ratify KPMG auditor - MSN
Early ZYCUBO treatment cut death risk nearly 80% in children with Menkes - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Mersana Therapeutics (NASDAQ:MRSN) Upgraded at Wall Street Zen - MarketBeat
Karyopharm (NASDAQ: KPTI) plans big share authorization increase to fund 2026 trials - stocktitan.net
Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - Улправда
3.03%
2.20%
Capitalizzazione:
|
Volume (24 ore):